These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 26936058)

  • 21. An open-label study of guanfacine extended release for traumatic stress related symptoms in children and adolescents.
    Connor DF; Grasso DJ; Slivinsky MD; Pearson GS; Banga A
    J Child Adolesc Psychopharmacol; 2013 May; 23(4):244-51. PubMed ID: 23683139
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A prospective open trial of guanfacine in children with pervasive developmental disorders.
    Scahill L; Aman MG; McDougle CJ; McCracken JT; Tierney E; Dziura J; Arnold LE; Posey D; Young C; Shah B; Ghuman J; Ritz L; Vitiello B
    J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):589-98. PubMed ID: 17069547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Psychiatric comorbidity in children and adolescents with restless legs syndrome: a retrospective study.
    Pullen SJ; Wall CA; Angstman ER; Munitz GE; Kotagal S
    J Clin Sleep Med; 2011 Dec; 7(6):587-96. PubMed ID: 22171196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Childress AC
    Adv Ther; 2012 May; 29(5):385-400. PubMed ID: 22610723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [An update on the pharmacological treatment of attention deficit hyperactivity disorder: lisdexamphetamine and extended-release guanfacine].
    Martin Fernandez-Mayoralas D; Fernandez-Perrone AL; Munoz-Jareno N; Fernandez-Jaen A
    Rev Neurol; 2017 Mar; 64(s02):S1-S8. PubMed ID: 28272733
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
    Dittmann RW; Schacht A; Helsberg K; Schneider-Fresenius C; Lehmann M; Lehmkuhl G; Wehmeier PM
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):97-110. PubMed ID: 21488751
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An open-label, prospective study of guanfacine in children with ADHD and tic disorders.
    Boon-yasidhi V; Kim YS; Scahill L
    J Med Assoc Thai; 2005 Nov; 88 Suppl 8():S156-62. PubMed ID: 16856436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial.
    Sallee FR; McGough J; Wigal T; Donahue J; Lyne A; Biederman J;
    J Am Acad Child Adolesc Psychiatry; 2009 Feb; 48(2):155-65. PubMed ID: 19106767
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risperidone use in children with Down syndrome, severe intellectual disability, and comorbid autistic spectrum disorders: a naturalistic study.
    Capone GT; Goyal P; Grados M; Smith B; Kammann H
    J Dev Behav Pediatr; 2008 Apr; 29(2):106-16. PubMed ID: 18349709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and Pharmacologic Considerations for Guanfacine Use in Very Young Children.
    Black BT; Soden SE; Kearns GL; Jones BL
    J Child Adolesc Psychopharmacol; 2016 Aug; 26(6):498-504. PubMed ID: 26894823
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between Early Guanfacine Discontinuation and Somnolence for Attention-Deficit/Hyperactivity Disorder.
    Doi K; Sogawa R; Eguchi Y; Matsuo M; Shimanoe C
    Biol Pharm Bull; 2024; 47(6):1204-1208. PubMed ID: 38910124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder.
    Taylor FB; Russo J
    J Clin Psychopharmacol; 2001 Apr; 21(2):223-8. PubMed ID: 11270920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
    Biederman J; Melmed RD; Patel A; McBurnett K; Konow J; Lyne A; Scherer N;
    Pediatrics; 2008 Jan; 121(1):e73-84. PubMed ID: 18166547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is there a relationship between attention deficit/hyperactivity disorder and manic symptoms among children with mental retardation of unknown etiology?
    Fidan T; Kirpinar I; Oral M; Koçak K
    Compr Psychiatry; 2011; 52(6):644-9. PubMed ID: 21310401
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination treatment with guanfacine extended release and blonanserin for Tourette's syndrome comorbid with attention deficit hyperactivity disorder.
    Kawabe K; Horiuchi F; Ueno SI
    Psychiatry Clin Neurosci; 2019 Dec; 73(12):762-763. PubMed ID: 31588606
    [No Abstract]   [Full Text] [Related]  

  • 36. Guanfacine extended release in the treatment of attention deficit hyperactivity disorder in children and adolescents.
    Connor DF; Rubin J
    Drugs Today (Barc); 2010 May; 46(5):299-314. PubMed ID: 20517532
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Response/remission with guanfacine extended-release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Cutler AJ; Brams M; Bukstein O; Mattingly G; McBurnett K; White C; Rubin J
    J Am Acad Child Adolesc Psychiatry; 2014 Oct; 53(10):1092-101. PubMed ID: 25245353
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extended-Release Guanfacine for Hyperactivity in Children With Autism Spectrum Disorder.
    Scahill L; McCracken JT; King BH; Rockhill C; Shah B; Politte L; Sanders R; Minjarez M; Cowen J; Mullett J; Page C; Ward D; Deng Y; Loo S; Dziura J; McDougle CJ;
    Am J Psychiatry; 2015 Dec; 172(12):1197-206. PubMed ID: 26315981
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Guanfacine extended release: a novel treatment for attention-deficit/hyperactivity disorder in children and adolescents.
    Faraone SV; McBurnett K; Sallee FR; Steeber J; López FA
    Clin Ther; 2013 Nov; 35(11):1778-93. PubMed ID: 24139092
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term safety and efficacy of guanfacine extended release in children and adolescents with ADHD.
    Huss M; Dirks B; Gu J; Robertson B; Newcorn JH; Ramos-Quiroga JA
    Eur Child Adolesc Psychiatry; 2018 Oct; 27(10):1283-1294. PubMed ID: 29442229
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.